Merck Investors Can't Use Vioxx News Report In Fraud MDL

Law360, New York (May 30, 2013, 4:12 PM EDT) -- A New Jersey federal judge on Wednesday allowed a class of Merck & Co. Inc. investors to tweak its securities fraud suit against the drugmaker for a sixth time but barred the inclusion of a 2004 news article, finding it didn't provide any new information about Merck's alleged knowledge of the possible risks of its painkiller Vioxx.

The opinion is a tempered victory for plaintiffs, who can now amend their complaint to include a 2000 statement they say misled shareholders to think a small group of...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.